Evidence map›Paper›PMID 41718856›Full record

ArticleClinical & experimental metastasis2026

Clinical utility of the ESTRO-EORTC classification in oligometastatic disease treated with stereotactic body radiotherapy: a single-institution retrospective study.

Masaaki Goto, Tetsuo Nonaka, Daiki Maruyama, Genki Ishii, Masatoshi Nakamura, Keiichiro Baba, Hazuki Nitta, Hideyuki Sakurai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masaaki GotoDepartment of Radiation Oncology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya, Tokyo, 150-8935, Japan. goto@pmrc.tsukuba.ac.jp.ORCID 0000-0003-3840-6527
Tetsuo NonakaDepartment of Radiation Oncology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya, Tokyo, 150-8935, Japan.
Daiki MaruyamaDepartment of Medical Technology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya, Tokyo, 150-8935, Japan.
Genki IshiiDepartment of Medical Technology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya, Tokyo, 150-8935, Japan.
Masatoshi NakamuraDepartment of Radiation Oncology & Proton Medical Research Center, Institute of Medicine, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.
Keiichiro BabaDepartment of Radiation Oncology & Proton Medical Research Center, Institute of Medicine, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.
Hazuki NittaDepartment of Radiation Oncology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya, Tokyo, 150-8935, Japan.
Hideyuki SakuraiDepartment of Radiation Oncology & Proton Medical Research Center, Institute of Medicine, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to classify patients who underwent stereotactic body radiotherapy (SBRT) for oligometastatic disease (OMD) at our institution using the consensus classification proposed by the European Society for Radiotherapy and Oncology and the European Organization for Research and Treatment of Cancer (ESTRO–EORTC) and to evaluate clinical outcomes based on this classification. Patients diagnosed with extracranial OMD who underwent SBRT, regardless of the primary tumour site, between April 2020 and December 2022 were retrospectively analysed. Based on the ESTRO–EORTC classification, cases were categorised into three OMD states: de novo, repeat, and induced OMD. We assessed overall survival (OS), local recurrence (LR) rates, and treatment-related adverse events (AEs). A total of 60 patients with 70 lesions were included, with a median follow-up of 24 months. All lesions were successfully classified according to the ESTRO–EORTC classification: 37 as de novo, 20 as repeat, and 13 as induced OMD. SBRT was delivered using the CyberKnife® system, with a median dose of 35 Gy in five fractions. The median OS for all patients was 71 months. The 1- and 2-year LR rates were 7.6% and 12%, respectively. Among OMD states, induced OMD had the poorest OS (median: 41 months), compared with de novo OMD (not reached) and repeat OMD (71 months). Only one Grade ≥ 3 AE was observed. All SBRT-treated OMD cases at our institution were successfully classified using the ESTRO–EORTC system. The classification showed potential prognostic value, suggesting its utility for stratifying patients with OMD.

Indexed as

Neoplasm Recurrence, LocalNeoplasmsRadiosurgeryAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesMetastasis-directed radiotherapyOligometastatic diseaseStereotactic body radiotherapy

Identifiers

PMID41718856
PMCPMC12923495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.